Ruella Lab

We focus on mechanisms of relapse after CAR-T therapy. Our goal is to design innovative combined IMT for relapsing/refractory Leukemia & Lymphoma. @MarcoRuella

[Ruella Lab @RuellaLab]

Ruella Lab is proud to support @MarcoRuella as a 2026 Visionaries of the Year candidate for Blood Cancer United!

Advancing therapies for blood cancers is at the heart of our work.

Help us reach $50K by June 12—every penny counts.

Donate & share 👇
🔗 https://t.co/6T1YgJGBJr

[Ruella Lab @RuellaLab]

For those of you in Philly, come support our bake sale in the Perelman Center upstairs lobby! 🍪 🍰

All proceeds will support Blood Cancer United! 🩸

[Ruella Lab @RuellaLab]

Great job to our PhD candidate Audrey for the wonderful presentation at @ISCTglobal! Read more about this work in our @ScienceTM publication.

Also great presentation by Dr. Bruce Levine (@BLLPHD), thank you for featuring our work from @CellCellPress

@MarcoRuella @PennMedicine

[Ruella Lab @RuellaLab]

Amazing presentation this morning at CCI, @PennCancer @PennMedCSO!

• @MarcoRuella presented correlative data from the Phase 1 Senza5-CAR5 study;
• @LemoineJean6 introduced a novel CAR T-cell design targeting IGHV1-69 on B-cell receptors.

Proud to help develop next-gen CAR T!

[Penn Medicine CSO @PennMedCSO]

Harnessing the CD2 axis to broaden & enhance the efficacy of CAR T-cell therapies ft. @AlbertoCarturan, @Mat_Angelos & @MarcoRuella (@PennCancer) @RuellaLab @BloodPortfolio https://t.co/wJvKVP9TVk

[Ruella Lab @RuellaLab]

Congrats to @BernhardDumoul1, @KSusztak, and the rest of the Susztak lab for the amazing work in @Nature! We are happy to be involved, and excited to see what comes next!

@PennMedicine @MarcoRuella

[Katalin Susztak @KSusztak]

🗞️📸🌟🤩Beautiful work led by @BernhardDumoul1 with the team builds a single cell spatial atlas of human DKD using Xenium + CosMx + snRNA-seq. @Nature This is not incremental. This is a new layer of pathology. Diabetic kidney disease (DKD) is still treated as one disease. That is the problem. Patients look similar clinically but behave very differently. We asked: is there a biologically distinct subgroup we are missing?
https://t.co/Au83tayvR9

[Ruella Lab @RuellaLab]

Thank you @PennMedicine for the support! And of course thank you @CellCellPress @BloodPortfolio @ScienceTM and @NEJM (out soon) for the opportunity to publish with you all!

[Ruella Lab @RuellaLab]

A celebration dinner for all of our recent accomplishments!

⭐️ 4 publications out so far in 2026
⭐️ 2 covers (@BloodPortfolio Vol 147 Issue 16, and @ScienceTM Vol 18 Issue 835)

And so much more to come!

@MarcoRuella

[Blood Journals Portfolio @BloodPortfolio]

CD2 is a viable target for CAR T-cell immunotherapy for T-cell malignancies, but CD2 deletion in CAR T cells can lead to dysfunction. Read in Blood: https://t.co/ALzcTAXHax

[Ruella Lab @RuellaLab]

‼️Ruella Lab at the Heme Malignancies Research in Progress session!

Presenters:
🩸@Shan_Liu_ discusses how host factors such as diet can modulate responses to CAR T-cell therapy

🩸@paruzzol presents on the decade-long persistence of CAR T-cells

@MarcoRuella @PennMedicine

[Blood Journals Portfolio @BloodPortfolio]

New issue of Blood out now featuring Anti-CD2 CAR T-cells for T-cell neoplasms, Inflammatory landscape in clonal hematopoiesis, GRK5 variant linked to thrombotic disease, and more. Explore here: https://t.co/TkReJPJRk3

[Ruella Lab @RuellaLab]

📣Out today in @BloodPortfolio: harnessing the CD2 axis to broaden and enhance the efficacy of CAR T-cell therapies.

🔗 https://t.co/Nt1f9VFLsI

Congrats to @AlbertoCarturan & @Mat_Angelos!

@MarcoRuella @PennMedicine @PennCancer @PennMedCSO

[Ruella Lab @RuellaLab]

@ASH_hematology Thank you for highlighting our lab! This snapshot is just one small piece of the broader effort that keeps hematology strong and advancing—especially in challenging times.

[ASH @ASH_hematology]

When political threats put scientific research at risk, your support of the ASH Foundation helped keep hematology vibrant and rewarding. Thank you for driving positive change in hematology. View the 2025 ASH Annual Report: https://t.co/D0VJB410J2
#Fight4Hematology

[Penn Medicine CSO @PennMedCSO]

New research out @CellCellPress in finds that β-hydroxybutyrate enhances the metabolic fitness of CAR T cells in cancer ft. @Shan_Liu_ & @RuellaLab (@PennCancer) https://t.co/6aAq13Wyfl

[Arc Institute @arcinstitute]

CAR T cell therapy has shown strong results against certain cancers, but metabolic exhaustion limits its effectiveness over time.

In @CellCellPress, the @MaayanLevyPhD & @ChristophThaiss labs report that a common supplement can fuel CAR T cells to fight cancer more effectively.

[Maayan Levy @MaayanLevyPhD]

Excited to share our new paper in @CellCellPress with @MarcoRuella, led by @Shan_Liu_
and @PuneethGuru_. CAR T cell therapy loses effectiveness over time due to metabolic exhaustion, but we found a surprisingly simple approach to address it. 👇

https://t.co/WXN9834SbE

[Ruella Lab @RuellaLab]

Finally out 📣
Ketogenic diet–derived β-hydroxybutyrate boosts CAR T cell metabolism and function. Congrats
@Shan_Liu_ and @PuneethGuru_ !
@MarcoRuella @MaayanLevyPhD
@PennMedicine @PennMedCSO @PennCancer @CellCellPress

https://t.co/nrM41uVjTI

[ANSA Scienza&Tecnica @AnsaScienza]

Ha distrutto le cellule tumorali presenti nei topi con la stessa efficacia ma senza attaccare anche quelle sane del sistema immunitario. E' la nuova terapia Car-T, che apre la strada verso futuri trattamenti senza effetti collaterali
@Penn
@MyUniSR
https://t.co/cvt7WqbupT

[Science Translational Medicine @ScienceTM]

A new design for #CARTcells that targets IGHV4-34 on B cell receptors can suppress lymphoma cells in vivo and neutralizes autoimmune #lupus B cells from patients, while avoiding off-target killing of healthy B cells. @MarcoRuella @PennCancer https://t.co/raplWkWK1S